Want to see IEX full AI Analyst Report?
Adjusted EBITDA By Segment
Shows profitability across various business segments, indicating operational efficiency and helping assess which segments contribute most to overall financial health.IDEX's Health & Science Technologies segment is showing strong recovery, reaching record order levels and expanding margins, driven by pharmaceuticals and data centers. This contrasts with the Fire & Safety/Diversified Products segment, which faces declining sales due to soft volumes and macroeconomic pressures. Fluid & Metering Technologies remains stable with moderate growth. The company's strategic acquisitions and focus on shareholder returns signal confidence despite challenges, as reflected in their narrowed EPS guidance and robust cash flow performance.
Date | Fluid & Metering Technologies | Health & Science Technologies | Fire & Safety/Diversified Products | Corporate Office & Other |
|---|---|---|---|---|
Mar 31, 2026 | $98.70M | $106.00M | $55.80M | -$30.10M |
Dec 31, 2025 | $111.10M | $94.90M | $53.60M | -$18.70M |
Sep 30, 2025 | $105.40M | $106.80M | $49.30M | -$21.70M |
Jun 30, 2025 | $95.00M | $108.70M | $56.40M | -$22.90M |
Mar 31, 2025 | $95.30M | $87.40M | $54.20M | -$28.90M |
Dec 31, 2024 | $94.70M | $98.60M | $54.30M | -$20.10M |
Sep 30, 2024 | $98.50M | $82.60M | $54.70M | -$21.50M |
Jun 30, 2024 | $107.70M | $84.20M | $53.80M | -$21.50M |
Mar 31, 2024 | $105.40M | $81.40M | $51.40M | -$29.90M |
Dec 31, 2023 | $92.20M | $80.70M | $51.60M | -$20.90M |